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Abstract Previous preclinical and clinical ﬁndings have
suggested a potential role of epidermal growth factor
receptor (EGFR) in osteoclast differentiation and the
pathogenesis of bone metastasis in cancer. In this study, we
investigated the effect of erlotinib, an orally active EGFR
tyrosine kinase inhibitor (TKI), on the bone invasion of
human non-small-cell lung cancer (NSCLC) cell line
NCI-H292. First, we established a novel osteolytic bone
invasion model of NCI-H292 cells which was made by
inoculating cancer cells into the tibia of scid mice. In this
model, NCI-H292 cells markedly activated osteoclasts
in tibia, which resulted in osteolytic bone destruction.
Erlotinib treatment suppressed osteoclast activation to the
basal level through suppressing receptor activator of
NF-jB ligand (RANKL) expression in osteoblast/stromal
cell at the bone metastatic sites, which leads to inhibition of
osteolytic bone destruction caused by NCI-H292 cells.
Erlotinib inhibited the proliferation of NCI-H292 cells in in
vitro. Erlotinib suppressed the production of osteolytic
factors, such as parathyroid hormone-related protein
(PTHrP), IL-8, IL-11 and vascular endothelial growth
factor (VEGF) in NCI-H292 cells. Furthermore, erlotinib
also inhibited osteoblast/stromal cell proliferation in vitro
and the development of osteoclasts induced by RANKL in
vitro. In conclusion, erlotinib inhibits tumor-induced oste-
olytic invasion in bone metastasis by suppressing osteoclast
activation through inhibiting tumor growth at the bone
metastatic sites, osteolytic factor production in tumor cells,
osteoblast/stromal cell proliferation and osteoclast differ-
entiation from mouse bone marrow cells.
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Abbreviation
EGFR Epidermal growth factor receptor
NSCLC Non-small-cell lung cancer
PTHrP Parathyroid hormone-related protein
VEGF Vascular endothelial growth factor
SRE Skeletal-related event
TKI Tyrosine kinase inhibitor
MEM Minimum essential medium
HE Hematoxylin and eosin
TRAP Tartrate-resistant acid phosphatase
ALP Alkaline phosphatase
OPG Osteoprotegerin
RANKL Receptor activator of NF-jB ligand
Introduction
Non-small-cell lung cancer (NSCLC) is the most common
type of lung cancer, accounting for approximately 80% of
lung cancers. Bone metastases occur in 30–40% of NSCLC
patients, and are often associated with signiﬁcant morbidity
[1]. Common bone metastatic complications, which are also
called skeletal-related events (SREs), include bone pain,
pathological fractures, malignant hypercalcemia and spinal
cord compression. These SREs are clinically meaningful
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decreased quality of life. Zoledronic acid is one of the
widely used bisphosphonates that has been demonstrated to
signiﬁcantly prevent SREs in lung cancer patients with bone
metastases. However, there are no signiﬁcant differences in
time of bone-lesion progression and median survival
between zoledronic acid and a placebo [2]. Thus, it is
necessary to develop an effective therapy that could inhibit
the tumor growth and extend survival in NSCLC patients
with bone metastases.
Erlotinib is an oral, small-molecule epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI)
that reversibly binds to the intracellular tyrosine kinase
domain of EGFR and is used as a standard treatment for
previously-treated advanced NSCLC. The expression of
EGFR and its ligand has been found in the majority of
human carcinoma. Erlotinib blocks autophosphorylation
of EGFR with subsequent inhibition of the downstream
signaling cascades involving RAS/RAF/MAPK and PI3K/
AKT. The EGFR signaling network, one of important
process involved in tumor progression affecting cell pro-
liferation, inhibition of apoptosis, metastasis and angio-
genesis, is often dysregulated in cancer cells [3]. Erlotinib
monotherapy has been favorable to the presence of
EGFR mutations and both EGFR and KRAS wild-types in
NSCLC [4].
In clinical studies, treatment with EGFR-TKI, erlotinib
or geﬁtinib, for NSCLC patients with bone metastases was
reported to signiﬁcantly decrease bone pain, to improve
pathologic fractures, to prolong disease control of bone
metastatic site and also to signiﬁcantly extend overall
survival [5–9]. Although, these clinical observations indi-
cate the possibility of EGFR signal involvement in the
progression of bone metastases of NSCLC, there are no
prospective, large size clinical studies.
In preclinical studies, various activities of EGFR-TKI on
the pathogenesis and progression of bone metastases of
prostate cancer and renal cancer have been described in
previous reports [10–12]. Normanno et al. [13] described
that geﬁtinib has a potential in bone metastases by inhib-
iting the ability of human bone marrow stromal cells to
induce osteoclast differentiation. Moreover, a number of
different mechanisms have been suggested to be involved
in these effects [14]. However there has been no report to
show an activity of EGFR-TKI on bone metastases of
NSCLC cells.
In this study, for evaluating whether or not erlotinib
would be effective for bone metastases of NSCLC, we tried
to establish a novel osteolytic bone invasion model which
resembles the clinical characteristics of NSCLC. Then we
examined whether erlotinib could be a useful agent for
bone metastases of NSCLC using our novel osteolytic bone
invasion model.
Materials and methods
Chemicals
Erlotinib was provided by F. Hoffman-La Roche Ltd.
(Basel, Switzerland). Erlotinib was dissolved in DMSO for
the in vitro assay and in 6% Captisol
 (CyDex Pharma-
ceuticals, Inc., Lenexa, KS) solution for the in vivo
experiment. Captisol was dissolved in distillated water.
Cell lines
Human NSCLC cell line NCI-H292, human osteoblast cell
line MG-63 and human stromal cell line HS-5 were pur-
chased from the American Type Culture Collection
(ATCC, Manassas, VA) and maintained in RPMI1640
(Sigma-Aldrich Co., Ltd., St. Louis, MO) supplemented
with 10% FBS (Japan Bio Serum Co., Ltd., Fukuyama,
Japan). Mouse osteoblastic cell line MC3T3-E1 and mouse
stromal cell line ST2 were purchased from RIKEN Bio-
Resource Center (Tsukuba, Japan) and maintained in
aMEM (Invitrogen, Carlsbad, CA) and in RPMI1640
supplemented with 10% FBS, respectively. Mouse primary
osteoblasts were purchased from Primary Cell Co., Ltd.
(Sapporo, Japan) and maintained in aMEM supplemented
with 10% FBS. All cells were cultured at 37Ci n5 %C O 2.
Animals
Male 5-week-old ddY mice, BALB-nu/nu mice and scid
mice were purchased from Japan SLC, Inc. (Hamamatsu,
Japan), Charles River Japan, Inc. (Yokohama, Japan) and
Clea Japan, Inc. (Osaka, Japan), respectively. Animals
were housed in a pathogen-free environment under
controlled conditions (temperature: 20–26C, humidity:
40–70%, light–dark cycle: 12–12 h). Chlorinated water
and irradiated food were provided ad libitum. The ani-
mals were allowed to acclimatize and recover from
shipping-related stress for more than 7 days prior to the
study. The health of the mice was monitored daily. All
animal protocols were reviewed by the Institutional
Animal Care and Use Committee of Chugai Pharma-
ceutical Co., Ltd and all animal experiments were per-
formed in accordance with the ‘Guidelines for the
Accommodation and Care of Laboratory Animals’ of
Chugai Pharmaceutical Co., Ltd.
Intratibial osteolytic bone invasion model
of NCI-H292 cells
Tibial implantation of NCI-H292 cells was performed as
described [15]. Brieﬂy, 2 9 10
5 NCI-H292 cells in 20 llo f
culture medium/matrigel (BD Biosciences, San Jose, CA)
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domly divided into two groups of 10 mice on day 1. The
mice were administered once daily either oral erlotinib
(75 mg/kg/day) or Captisol, as a vehicle control, starting
from day 1 for 27 days. The mice were also subjected to
deep anaesthesia and exposed to soft X-rays at 30 kV for
2 s with SOFRON (SOFRON Co., Ltd., Tokyo, Japan) on
days 14, 21 and 28 as described [16]. The radiophotographs
were scanned with a digital camera (Nicon, Tokyo, Japan),
and the number and the area of osteolytic foci of bone
metastases in the whole tibia were measured using an
image analyzing software (WinROOF, Mitani Corporation,
Fukui, Japan).
Histologic and histomorphometric analysis
of osteolytic lesions
The tibias of mice treated daily with either erlotinib or
vehicle from day 1 to day 13 were collected on day 14, and
ﬁxed in 4% paraformaldehyde. The specimens were
decalciﬁed in EDTA and embedded in parafﬁn. Thin sec-
tions were stained with hematoxylin and eosin (HE)
staining, tartrate-resistant acid phosphatase (TRAP) stain-
ing. Immunohistochemical stainings were also performed
using anti-mouse receptor activator of NF-jB ligand
(RANKL) antibody (R&D systems, Minneapolis, MN),
anti-phospho-EGFR (Y1068) antibody or anti-Ki-67 anti-
body (Abcam, Cambridge) as described [17] and according
to the manufacturer’s instructions. The tibias were col-
lected on day 14, and ﬁxed in 70% ethanol. The specimens
were embedded in glycolmethacrylate. Thin sections were
stained with alkaline phosphatase (ALP)/TRAP double
staining. Histomorphometric analysis of the tumor burden,
tumor proliferation and number of osteoclasts in tibia was
performed using the proximal sections stained with HE,
Ki-67 and TRAP, respectively. The tumor area was mea-
sured using image analyzing software (Scion, Frederick,
MD). The number of activated osteoclasts was determined
by counting the multinucleated ([4 nuclei) TRAP-positive
cells under a light microscope.
Immunoblotting
Immunoblotting was performed as described [18]. Brieﬂy,
cultured cells were lysed in lysis buffer and the 20 lg
protein lysates were separated on 7.5% SDS-PAGE and
then transferred onto the membrane. Antibodies against
EGFR, phospho-EGFR (Y1068), ERK, phospho-ERK,
AKT, phospho-AKT (S473) (Cell Signaling Technology,
Inc., Danvers, MA) and anti-b-actin (Sigma-Aldrich) were
used for immunoblotting.
In vitro cell proliferation assay
Cells were seeded 1 9 10
3 cells/well in 96-well plates.
From the following day, the cells were treated with erl-
otinib for 4 days and then MTT assays were done using
WST-8 solution (Dojindo, Tokyo, Japan) according to the
manufacturer’s instructions. The viability of cells was
calculated as: [(mean absorbance of erlotinib-treated wells
- mean absorbance of cell-free wells)/(mean absorbance
of vehicle wells - mean absorbance of cell-free wells)] 9
100.
Coculture of NCI-H292 cells and mouse primary
osteoblasts or stromal cells
To evaluate interaction between these cells, three coculture
conditions were performed as described previously [18].
Brieﬂy, 1 9 10
4 mouse primary osteoblasts or stromal cell
line ST2 were cocultured with NCI-H292 conﬂuent cell
monolayer with or without 3% paraformaldehyde ﬁxation.
Or 1 9 10
4 mouse primary osteoblasts/ST2 cells were
cocultured with 1 9 10
5 NCI-H292 cells in suspension
with or without a an 8.0 lm pore size cell culture insert
(Corning, Inc., Lowell, MA) to separate from each cell.
After 8 h coculture, cDNA of primary osteoblasts and ST2
were synthesized using the Cells-to-cDNA kit (Ambion,
Inc., Austin, TX), and the real-time RT-PCR was per-
formed to examine the mouse RANKL, osteoprotegerin
(OPG) and actin mRNA expression level using LightCycler
system (Roche Diagnostics, Ltd., Basel, Switzerland).
Applied Biosystems Assay-on-Demand primer probe sets
for the detection of mouse RANKL, OPG and actin were
used with Mm00441908m1, Mm00446190m1 and
Mm00435452m1, respectively (Life Technologies Co.,
Ltd., Carlsbad, CA). Relative gene expression compared to
non-treated cells was quantiﬁed using the comparative
threshold cycle (CT) method by subtracting the internal
control of actin CT value from the RANKL or OPG CT
value. These CT values were calculated by the 2nd deriv-
ative maximum method in LightCycler system.
In vitro production of osteolytic factors
in NCI-H292 cells
The 2 9 10
6 NCI-H292 cells were seeded in 6-well plates.
On the following day, cells were treated with erlotinib for
1 day and then protein levels of osteolytic factors (para-
thyroid hormone-related protein (PTHrP), IL-1b,6 ,8 ,1 0 ,
11, GM-CSF, TNF-a and vascular endothelial growth
factor (VEGF)) [19–21] in the culture media and the cel-
lular DNA contents were determined by immunoassays and
a double-strand DNA Quantiﬁcation Kit (Invitrogen).
PTHrP and IL-11 were measured by IRMA in Mitsubishi
Clin Exp Metastasis (2011) 28:649–659 651
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ELISA kit (R&D systems), respectively. The others were
measured by Bio-plex human cytokine assays (Bio-Rad
Laboratories, Inc., Hercules, CA). The protein level of
osteolytic factors normalized by the DNA contents were
calculated as: [(concentration of erlotinib-treated wells
- mean concentration of cell-free wells)/DNA contents of
erlotinib-treated wells]/[(concentration of vehicle-treated
wells - mean concentration of cell-free wells)/DNA con-
tents of vehicle-treated wells] 9 100. The data were shown
as mean ? SD of duplicates.
In vitro osteoclast differentiation from mouse bone
marrow cells
The protocol was performed as described [22]. Brieﬂy,
mouse bone marrow cells were isolated from 6 to
10-week-old male ddY mice and then cultured in aMEM
supplemented with 10% FBS, 30 ng/ml mouse M-CSF
(Wako Pure Chemical Industries, Ltd., Osaka, Japan) and
30 ng/ml mouse RANKL (Wako) with or without erlotinib.
After osteoclast differentiation, cells were ﬁxed and stained
with TRAP. The number of osteoclasts was determined
by counting the multinucleated ([3 nuclei) TRAP-positive
cells under a microscope. The data were shown as mean ?
SD of quadruplicates.
Statistical analysis
The Wilcoxon test was used to detect the statistical differ-
ences in tumor volume. Probability values \0.05 were
considered to be signiﬁcant. The t test was used to detect the
statistical differences in number of osteoclasts. Probability
values\0.05 were considered to be signiﬁcant. Statistical
analyses were performed using an SAS preclinical package
(version 8.2; SAS Institute, Inc., Cary, NC).
Results
Establishment of mouse osteolytic bone invasion model
of NCI-H292 cells
To examine the effects of erlotinib on bone metastasis of
NSCLC, we established a novel in vivo intratibial osteo-
lytic bone invasion model of the human NSCLC cell line
NCI-H292. In mice injected with NCI-H292 cells into
tibia, osteolytic bone lesions appeared from day 14 and
expanded in a time-dependent manner (Fig. 1a, b). The
tumor take rate in this model was 90% (osteolytic bone
lesions were observed only in eighteen of twenty legs
inoculated on day 28). ALP/TRAP double staining dem-
onstrated that many TRAP-positive activated osteoclasts
were present within the ALP-positive osteoblast/stromal
cell layer covering the bone surfaces close to the metastatic
tumor (Fig. 1c). In contrast, activated osteoclasts could
hardly be seen in normal mouse (Fig. 1c). These ﬁndings
indicate that direct contact between NCI-H292 tumor cells
and osteoblasts/stromal cells induced the activation of
osteoclastic precursors in the metastatic lesions.
NCI-H292 cell-induced RANKL expression in mouse
osteoblasts/stromal cells ST2
Osteoclasts are developed by cellular interaction between
osteoclastic precursors and osteoblasts or stromal cells
thorough RANK-RANKL signal transduction [23]. To
examine the mechanism of NCI-H292 cell-induced osteo-
clast activation in this model, we investigated the effects of
NCI-H292 cells on RANKL expression in mouse primary
osteoblasts and mouse stromal cells ST2. The expression of
RANKL mRNA in osteoblasts/ST2 cells was drastically
increased when cultured with live adherent NCI-H292
cells, but were strongly abolished when cultured with
ﬁxed tumor cells (Fig. 1d). Furthermore, RANKL mRNA
expression in osteoblasts/stromal cells was also drastically
increased when cultured with NCI-H292 cells in suspen-
sion, but were strongly abolished when cultured apart from
tumor cells (Fig. 1d). In contrast, there was almost no
change in OPG expression in osteoblasts/stromal cells
when these were cocultured with adhesion and suspension
of NCI-H292 cells (data not shown). These ﬁndings indi-
cate that not only cell-to-cell direct contact but also any
soluble factors from tumor cells are indispensable for NCI-
H292 cell-induced RANKL expression in osteoblasts/
stromal cells.
Inhibitory effects of erlotinib on osteolytic bone
invasion model of NCI-H292 cells
Administration of erlotinib signiﬁcantly decreased the area
and incidences of NCI-H292 cell-induced osteolytic lesions
on days 21 and 28 (Fig. 2a, b, c). Administration of erl-
otinib starting from days 7 or 14 exerted almost the same
inhibitory effects of osteolytic lesions on day 28 as starting
from day 1 (data not shown). A difference in body weight
loss was not observed in the erlotinib treatment group
compared with the vehicle group on days 21 and 28 (data
not shown). Furthermore, erlotinib completely suppressed
the tumor induced-RANKL expression in osteoblasts/stro-
mal cells (Fig. 2d). Erlotinib markedly suppressed the
osteoclast activation to the basal level of non-tumor bear-
ing mouse (P = 0.07) (Fig. 2e, f). These ﬁndings indicate
that erlotinib inhibited osteolytic bone destruction of NCI-
H292 cells in the tibia by inhibiting the accumulation of
activated osteoclasts.
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of NCI-H292 cells in vivo and in vitro
Administration of erlotinib tended to inhibit the metastatic
tumor growth in this osteolytic bone invasion model
(P = 0.24) (Fig. 3a, b). The reduced cell proliferative
activity of NCI-H292 cells was observed by immuno-
staining of proliferative markers Ki-67 (P = 0.24)
(Fig. 3c). Furthermore, erlotinib showed a marked inhibi-
tion of NCI-H292 cell proliferation in vitro in a dose-
dependent manner, and the IC50 value was 0.11 lM
(Fig. 3d). An addition of 1 lM of erlotinib markedly
blocked not only EGFR phosphorylation but also ERK and
Akt phosphorylation which are the downstream of EGFR
signaling cascades in NCI-H292 cells (Fig. 3e). Mean-
while, phosphorylated EGFR expression in tumor cells at
the metastatic sites was detected in not only the vehicle
treatment but also the erlotinib treatment, a difference of
the level of EGFR phosphorylation was not observed with
or without erlotinib treatment (Fig. 3f).
Inhibitory effects of erlotinib on production
of osteolytic factor in NCI-H292 cells
To elucidate the soluble factorfrom NCI-H292 cells which is
related to RANKL expression in osteoblasts/ST2 cells, we
investigated the production of major osteolytic factors
including PTHrP, IL-6 and IL-8 etc. As a result, NCI-H292
cellsproducedasufﬁcientamountofPTHrP,IL-6,IL-8,IL-11
and VEGF but the production of IL-1b,I L - 1 0 ,G M - C S Fa n d
TNF-a was lower than the detection limit (data not shown).
Erlotinib blocked the production of PTHrP, IL-8, IL-11 and
VEGF in NCI-H292 cells in a dose-dependent manner
(Fig. 4). Meanwhile, IL-6 production was not changed by
erlotinib treatment, indicating that IL-6 expression is inde-
pendent of the EGFR signal in NCI-H292 cells (Fig. 4).
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osteolytic foci. Arrowheads
indicate the osteolytic foci.
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123Inhibitory effects of erlotinib on cell proliferation
of osteoblasts/stromal cells and osteoclast
differentiation from mouse bone marrow cells
Recently, the role of EGFR in osteoblast and osteoclast has
been focused on [5, 24]. Therefore, we examined the
effects of erlotinib on these cells. The mouse primary
osteoblasts, mouse osteoblastic cell line MC3T3-E1, mouse
stromal cell line ST2, human osteoblastic cell line MG-63
and human stromal cell line HS-5 expressed EGFR
(Fig. 5a). Erlotinib inhibited the proliferation of these cell
lines in vitro (Fig. 5b, c). In contrast, the reduced cell
proliferative activity of osteoblasts/stromal cells in vivo by
erlotinib treatment could not be estimated, because there
was no detectable Ki-67 immunostaining in osteoblasts/
stromal cells with or without erlotinib treatment (data not
shown). In addition, erlotinib completely suppressed the
formation of mononuclear and multinuclear TRAP-positive
cells in a dose-dependent manner (Fig. 5d, e), although
erlotinib did not exhibit any cytotoxity against bone mar-
row cells in this condition (data not shown).
Discussion
Bone is one of the commonest target organs of distant
metastasis in lung cancer [25]. Many steps are involved in
the metastasis from primary site to bone; that is, new vessel
formation, invasion, arrest in secondary capillary beds,
extravasation, adaptation to bone microenvironment and
proliferation of cancer cells in bone [26, 27]. The main
mechanism responsible for bone destruction is considered
to be bone resorption, caused not directly by tumor cells
but by tumor cell-activated osteoclasts through interaction
with osteoblasts/stromal cells, which altogether form a
‘‘vicious circle’’ [28]. In the present study, we investigated
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123the role of EGFR in the vicious circle of NSCLC bone
metastasis by examining whether EGFR-TKI has the
potential to inhibit bone metastases of NSCLC cells.
Although the effects of EGFR-TKI on bone metastases in
NSCLC patients have not been investigated in a large clin-
ical study, occasional reports have suggested a potential
activityofthisdrugontheprogressionofbonedisease[5–9].
Recently, Okano et al. [6] have reported cases of NSCLC in
which geﬁtinib, an EGFR-TKI, showed a dramatic response
to pathological fractures due to bone metastases and
eventually the fractures were almost completely healed.
Moreover, geﬁtinib showed a signiﬁcant improvement of
metastatic bone pain in breast cancer [29]. However, the
impact of EGFR-TKI on bone metastases seems to be dif-
ferent in each patient.
To evaluate the potential of erlotinib on bone metastases
in preclinical study, we tried to establish a novel bone
invasion model using NSCLC cell line NCI-H292. Because
the experimental bone metastasis models of NSCLC cells
were very limited. NCI-H292 cells carry wild-types of both
EGFR and KRAS, which are the most major characteristics
(60–76%) in all NSCLC patients [30, 31]. This is the ﬁrst
osteolytic bone invasion model using a NSCLC cell line
with both EGFR and KRAS wild-types. In this model, our
histological studies showed that osteolytic bone destruction
induced by NCI-H292 cells is caused by activated
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123osteoclast accumulation in the metastatic lesions through
the interaction between NCI-H292 tumor cells and osteo-
blasts/stromal cells (Fig. 1). Furthermore, RANKL
expression in osteoblasts/stromal cells caused by NCI-
H292 cells was indispensable not only for cell-to-cell
contact but also some soluble factors, such as osteolytic
factors, from NCI-H292 tumor cells (Fig. 1). RANKL is a
critical osteoclast differentiation factor highly expressed on
the membranes of the osteoblasts/stromal cells in the bone
marrow environment [23]. RANKL combines with RANK,
a receptor of RANKL expressed in osteoclastic precursors,
and delivers intracellular signals involved in osteoclast
differentiation [19]. At the site of bone metastases,
RANKL is also considered as a direct mediator of tumor-
associated osteolytic lesions [32]. These ﬁndings indicate
that a vicious circle is formed in NCI-H292 osteolytic bone
invasion model.
The molecules involved in cell-to-cell recognition
between NCI-H292 cells and osteoblasts/stromal cells are
unclear. Integrins are reported to be candidates. Previous
reports have shown that osteoblasts as well as tumor cells
express various integrins, such as b1 integrin and avb3
integrin, and integrin signals regulate osteoclast formation
[33, 34]. However, we do not investigate whether or not
integrins are involved in interaction between NCI-H292
cells and osteoblasts/stromal cells, further studies are
needed to identify the molecules.
In the present study, erlotinib treatment suppressed
osteoclast activation, which led to inhibit osteolytic bone
destruction caused by NCI-H292 cells (Fig. 2). To clarify
the bone metastasis inhibitory mechanism of erlotinib
would be a useful approach to clinically select NSCLC
patients with bone metastases who could beneﬁt from erl-
otinib treatment. We demonstrated that erlotinib affects the
vicious circle of NCI-H292 osteolytic bone invasion which
results in inhibition of osteoclast activation. The effects of
erlotinib appear to be related to four different mechanisms:
the suppression of (1) tumor growth at the bone metastatic
sites, (2) osteolytic factor production, such as PTHrP, IL-6,
IL-8, IL-11 and VEGF in tumor cells, (3) osteoblasts/
stromal cell proliferation and (4) osteoclast differentiation
from mouse bone marrow cells (Fig. 6).
First, erlotinib strongly inhibited the proliferation of
NCI-H292 cells in vitro by blocking EGFR phosphoryla-
tion with subsequent inhibition of the downstream signal-
ing cascades involving RAS/RAF/MAPK and PI3K/AKT
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123(Fig. 3). The IC50 of NCI-H292 cells with both EGFR and
KRAS wild-types was 0.11 lM. Thus, NCI-H292 cells are
considered to be relatively sensitive to erlotinib. These
results suggest that erlotinib strongly inhibits the NCI-
H292 cell proliferation in in vitro by blocking the EGFR
signal transduction. In contrast, erlotinib did not inhibit the
phosphorylated EGFR expression in tumor cells at the bone
metastatic lesions (Fig. 3), which is inconsistent with
our in vitro result. It has been reported that the plasma
concentration of erlotinib in athymic nude mice correlates
well with erlotinib concentration in tumor. It is under
0.0025 lM 24 h after administration of 100 mg/kg erloti-
nib [35]. In this study, the tibiae were collected 24 h after
administration of 75 mg/kg erlotinib on day 13. Therefore,
the erlotinib concentration in NCI-H292 tumor concentra-
tion of erlotinib is considered to under 0.0025 lM, which is
insufﬁcient to block the EGFR phosphorylation. Thus the
reduced EGFR phosphorylation in tumor cells may not be
detectable even in case of erlotinib treatment.
Second, erlotinib strongly suppressed the production of
osteolytic factors, such as PTHrP, IL-8, IL-11 and VEGF in
NCI-H292 cells. RANKL expression in osteoblasts/stromal
cells is stimulated by various soluble osteolytic factors
including PTHrP, IL-6, IL-8, IL-11 which are produced by
tumor cells [27]. Especially, PTHrP plays an important role
in the development of osteolytic bone metastases in breast
cancer [36]. Usually, the addition of osteolytic factors is
essential for osteoclast formation in an in vitro coculture
system with osteoblasts. In addition, VEGF, a key regulator
of angiogenesis and vascular permeability [37], induces the
formation of novel vessels in bone metastatic lesions [14].
Our results showed that PTHrP, IL-8, IL-11 and VEGF are
produced in NCI-H292 cells and these factors were
markedly inhibited by erlotinib (Fig. 4). The mechanism
by which EGFR signal activation promotes PTHrP, IL-8,
IL-11 and VEGF production in NCI-H292 cells is currently
unknown. However, the production of these factors in NCI-
H292 cells may be regulated by ERK activation, because
ERK has been reported to stimulate the gene expression of
these factors in culture cells [37–39] and ERK phosphor-
ylation was completely blocked by erlotinib in NCI-H292
cells (Fig. 3). In contrast, the production of IL-6 in NCI-
H292 cells was not affected by erlotinib treatment for 24 h.
However, erlotinib markedly decreased IL-6 protein level
in conditioned media on day 4 compared to the vehicle-
treated cells, because the number of NCI-H292 cells was
decreased by erlotinib (data not shown). Therefore, IL-6 is
also decreased in this model by extended erlotinib treat-
ment, would be involved in suppression of bone metastases
of NCI-H292 cells.
Third, erlotinib inhibited the cell proliferation of oste-
oblasts/stromal cells. Recently, the role of EGFR in oste-
oblasts and osteoclastogenesis has been focused on
[13, 40]. Several studies have shown the expression of
EGFR in bone marrow mesenchymal stem cells (the pre-
cursor of osteoblasts), bone marrow stromal cells, osteo-
blasts and endothelial cells [13, 14, 41]. Furthermore,
EGFR ligands have been reported to stimulate the prolif-
eration of these cells [14, 41–43]. In the present study, we
showed that mouse as well as human osteoblasts/stromal
cells express EGFR and erlotinib inhibited the proliferation
of these cells in a dose-dependent manner in vitro (Fig. 5).
In contrast, the proliferative activity of osteoblasts/stromal
cells in vivo could not be estimated, because there was no
detectable Ki-67 immunostaining in osteoblasts/stromal
cells. The growth rate of osteoblasts/stromal cells in vivo
may be much slower than that of in vitro. Intriguingly,
EGFR ligands have been reported to regulate RANKL and
OPG expression in osteoblasts/stromal cells [13, 42]. OPG,
known as an osteoclastogenesis inhibitory factor, is a decoy
receptor of RANK and inhibits osteoclast differentiation by
interfering with the RANKL/RANK interaction [44].We
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123found that RANKL expression levels in primary osteo-
blasts decreased about 50% with erlotinib and there was no
change in RANKL expression levels of ST2 cells. In
contrast, OPG expression levels of either type of cell were
not changed (data not shown).
Fourth, erlotinib completely suppressed the RANKL-
induced osteoclast differentiation from mouse bone mar-
row cells without exhibiting cytotoxicity. Our results are
consistent with the previous reports. Wang et al. [24] have
shown that EGFR is expressed in osteoclasts and osteoclast
recruitment is impaired in EGFR deﬁcient mice. In addi-
tion, Yi et al. [40] have demonstrated that EGFR plays a
crucial role in RANKL-induced osteoclast differentiation
from mouse bone marrow cells by regulating RANKL-
activated signaling pathways through cross-talking with
RANK. These ﬁndings indicate that erlotinib may inhibit
the activation of osteoclasts by affecting on non-cancer
cells including osteoblasts/stromal cells and osteoclasts,
independently by affecting on NCI-H292 tumor cells.
Therefore, it is important to highlight the activity of anti-
EGFR agents on non-cancer cells including osteoblasts/
stromal cells and osteoclasts in the bone metastatic
microenvironment. Meanwhile, in clinical, abnormal bone
metabolism such as hypercalcemia and bone fracture has
not been reported as a side effects of erlotinib, therefore the
effects of erlotinib against osteoblasts/stromal cells and
osteoclasts may be speciﬁc in bone metastatic sites.
Meanwhile, only one cell line, NCI-H292, was used in
this study. We have tried to construct another bone
metastasis model for generalization of out NCI-H292
model using HCC827 EGFR-mutated NSCLC cell line.
Unfortunately, we could not establish HCC827 bone
metastasis model. Therefore, we used only the NCI-H292
osteolytic bone invasion model in the present study. Fur-
ther studies are needed to clarify whether or not erlotinib
could inhibit bone metastases in the other models. Addi-
tionally, in this NCI-H292 intra-tibial tumor inoculated
osteolytic bone invasion model, it could not be evaluated
whether erlotinib have a potential to inhibit forming bone
metastasis from primary site through the bloodstream.
However, anti-EGFR agents were reported to reduce
invasive capacity and angiogenic activity through the
inhibition of (1) molecules associated with tissue invasion
such as urokinase-type plasminogen activator (uPA) and
matrix metalloproteinase (MMP)-9, (2) the proliferation
and survival of endothelial cells and (3) the production of
VEGF in bone marrow stromal cells (14). Therefore, erl-
otinib would inhibit the progression of bone metastasis
from the primary site through the bloodstream.
Altogether, it is plausible that the inhibition of NCI-
H292 tumor growth and cell proliferation of osteoblasts/
stromal cells by erlotinib treatment would decrease the
chance of interaction between tumor cells and osteoblasts/
stromal cells, resulting in the suppression of the activation
of RANKL expression in osteoblasts/stromal cells.
In conclusion, we demonstrated that erlotinib inhibits
tumor-induced osteolytic invasion in bone metastasis by
suppressing metastatic tumor growth, osteolytic factor
production in tumor cells, osteoblasts/stromal cell prolif-
eration and osteoclast differentiation from mouse bone
marrow cells. These ﬁndings suggest that erlotinib has
potential therapeutic beneﬁts against bone metastases of
NSCLC and may be a useful therapeutic agent for the
treatment of NSCLC patients with bone metastases.
Finally, the evidence of our preclinical study would support
prospective clinical trials which will clarify the role of
erlotinib in the management of NSCLC patients with bone
metastases.
Acknowledgments We thank Mr. E. Onuma for special advice. The
authors indicated no potential conﬂicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Coleman RE (2001) Metastatic bone disease: clinical features,
pathophysiology and treatment strategies. Cancer Treat Rev
27(3):165–176
2. Hirsh VMD, Major PPMDF, Lipton AMD et al (2008) Zoledronic
acid and survival in patients with metastatic bone disease from
lung cancer and elevated markers of osteoclast activity. J Thorac
Oncol 3(3):228–236
3. Dancey J, Sausville EA (2003) Issues and progress with protein
kinase inhibitors for cancer treatment. Nat Rev Drug Discov
2(4):296–313
4. Schneider C-PMD, Heigener DMD, Schott-von-Romer KMD
et al (2008) Epidermal growth factor receptor-related tumor
markers and clinical outcomes with erlotinib in non-small cell
lung cancer: an analysis of patients from German centers in the
TRUST study. J Thorac Oncol 3(12):1446–1453
5. Pan M, Santamaria M, Wollman DB (2007) CNS response after
erlotinib therapy in a patient with metastatic NSCLC with an
EGFR mutation. Nat Clin Pract Oncol 4(10):603–607
6. Okano Y, Nishio M (2008) Efﬁcacy of geﬁtinib in treatment of
lung cancer patients with bone metastasis. Clin Calcium
18(4):527–533
7. Sugiura H, Yamada K, Sugiura T et al (2008) Predictors of sur-
vival in patients with bone metastasis of lung cancer. Clin Orthop
Relat Res 466(3):729–736
8. Zampa G, Moscato M, Brannigan BW et al (2008) Prolonged
control of bone metastases in non-small-cell lung cancer patients
treated with geﬁtinib. Lung Cancer 60(3):452–454
9. Satoh H, Ishikawa H, Ohara G et al (2009) Prolonged response to
geﬁtinib in bone metastasis. Med Oncol 26(1):101–102
10. Kim S-J, Uehara H, Karashima T et al (2003) Blockade of
epidermal growth factor receptor signaling in tumor cells and
tumor-associated endothelial cells for therapy of androgen-inde-
pendent human prostate cancer growing in the bone of nude mice.
Clin Cancer Res 9(3):1200–1210
658 Clin Exp Metastasis (2011) 28:649–659
12311. Weber KL, Doucet M, Price JE et al (2003) Blockade of epi-
dermal growth factor receptor signaling leads to inhibition of
renal cell carcinoma growth in the bone of nude mice. Cancer Res
63(11):2940–2947
12. Angelucci A, Gravina GL, Rucci N et al (2006) Suppression of
EGF-R signaling reduces the incidence of prostate cancer
metastasis in nude mice. Endocr Relat Cancer 13(1):197–210
13. Normanno N, De Luca A, Aldinucci D et al (2005) Geﬁtinib
inhibits the ability of human bone marrow stromal cells to induce
osteoclast differentiation: implications for the pathogenesis and
treatment of bone metastasis. Endocr Relat Cancer 12(2):
471–482
14. Normanno N, Gullick WJ (2006) Epidermal growth factor
receptor tyrosine kinase inhibitors and bone metastases: different
mechanisms of action for a novel therapeutic application? Endocr
Relat Cancer 13(1):3–6
15. Feeley BT, Liu NQ, Conduah AH et al (2006) Mixed metastatic
lung cancer lesions in bone are inhibited by Noggin overex-
pression and rank: Fc administration. J Bone Miner Res
21(10):1571–1580
16. Sasaki A, Kitamura K, Alcalde RE et al (1998) Effect of a newly
developed bisphosphonate, YH529, on osteolytic bone metastases
in nude mice. Int J Cancer 77(2):279–285
17. Amizuka N, Shimomura J, Li M et al (2003) Defective bone
remodelling in osteoprotegerin-deﬁcient mice. J Electron Microsc
(Tokyo) 52(6):503–513
18. Furugaki K, Iwai T, Kondoh K et al (2010) Antitumor activity of
erlotinib in combination with gemcitabine in in vitro and in vivo
modelsofKRAS-mutatedpancreaticcancers.OncolLett1:231–235
19. Yin JJ, Pollock CB, Kelly K (2005) Mechanisms of cancer
metastasis to the bone. Cell Res 15(1):57–62
20. Roodman GD (2007) Bone-breaking cancer treatment. Nat Med
13(1):25–26
21. Guise TA (2009) Breaking down bone: new insight into site-
speciﬁc mechanisms of breast cancer osteolysis mediated by
metalloproteinases. Genes Dev 23(18):2117–2123
22. Sakai S, Takaishi H, Matsuzaki K et al (2009) 1-Alpha,
25-dihydroxy vitamin D3 inhibits osteoclastogenesis through
IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab
27(6):643–652
23. Udagawa N, Takahashi N, Jimi E et al (1999) Osteoblasts/stromal
cells stimulate osteoclast activation through expression of
osteoclast differentiation factor/RANKL but not macrophage
colony-stimulating factor. Bone 25(5):517–523
24. Wang K, Yamamoto H, Chin JR et al (2004) Epidermal growth
factor receptor-deﬁcient mice have delayed primary endochon-
dral ossiﬁcation because of defective osteoclast recruitment.
J Biol Chem 279(51):53848–53856
25. Quint LE, Tummala S, Brisson LJ et al (1996) Distribution of
distant metastases from newly diagnosed non-small cell lung
cancer. Ann Thorac Surg 62(1):246–250
26. Chambers AF, Groom AC, MacDonald IC (2002) Metastasis:
dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer 2(8):563–572
27. Mundy GR (2002) Metastasis: metastasis to bone: causes, con-
sequences and therapeutic opportunities. Nat Rev Cancer
2(8):584–593
28. Yoneda T, Hiraga T (2005) Crosstalk between cancer cells and
bone microenvironment in bone metastasis. Biochem Biophys
Res Commun 328(3):679–687
29. von Minckwitz G, Jonat W, Fasching P et al (2005) A multicentre
phase II study on geﬁtinib in taxane- and anthracycline-pretreated
metastatic breast cancer. Breast Cancer Res Treat 89(2):165–172
30. Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations
in non-small-cell lung cancer: analysis of a large series of cases
and development of a rapid and sensitive method for diagnostic
screening with potential implications on pharmacologic treat-
ment. J Clin Oncol 23(4):857–865
31. Soung YH, Lee JW, Kim SY et al (2005) Mutational analysis of
EGFR and K-RAS genes in lung adenocarcinomas. Virchows
Arch 446(5):483–488
32. Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite
for cancer-associated osteolytic lesions. J Pathol 198(2):228–236
33. Matsuura N, Puzon-McLaughlin W, Irie A et al (1996) Induction
of experimental bone metastasis in mice by transfection of inte-
grin alpha 4 beta 1 into tumor cells. Am J Pathol 148(1):55–61
34. Zhao Y, Bachelier R, Treilleux I et al (2007) Tumor avb3 inte-
grin is a therapeutic target for breast cancer bone metastases.
Cancer Res 67(12):5821–5830
35. Higgins B, Kolinsky K, Smith M et al (2004) Antitumor activity
of erlotinib (OSI-774, Tarceva) alone or in combination in human
non-small cell lung cancer tumor xenograft models. Anti-cancer
Drugs 15(5):503–512
36. Bundred NJ, Ratcliffe WA, Walker RA et al (1991) Parathyroid
hormone related protein and hypercalcaemia in breast cancer.
BMJ 303(6816):1506–1509
37. Bancroft CC, Chen Z, Dong G et al (2001) Coexpression of
proangiogenic factors IL-8 and VEGF by human head and neck
squamous cell carcinoma involves coactivation by MEK-MAPK
and IKK-NF-jB signal pathways. Clin Cancer Res 7(2):435–442
38. Bamba S, Andoh A, Yasui H et al (2003) Regulation of IL-11
expression in intestinal myoﬁbroblasts: role of c-Jun AP-1- and
MAPK-dependent pathways. Am J Physiol Gastrointest Liver
Physiol 285(3):G529–G538
39. Lorch G, Gilmore JL, Koltz PF et al (2007) Inhibition of epi-
dermal growth factor receptor signalling reduces hypercalcaemia
induced by human lung squamous-cell carcinoma in athymic
mice. Br J Cancer 97(2):183–193
40. Yi T, Lee H-L, Cha J-H et al (2008) Epidermal growth factor
receptor regulates osteoclast differentiation and survival through
cross-talking with RANK signaling. J Cell Physiol 217(2):
409–422
41. Krampera M, Pasini A, Rigo A et al (2005) HB-EGF/HER-1
signaling in bone marrow mesenchymal stem cells: inducing cell
expansion and reversibly preventing multilineage differentiation.
Blood 106(1):59–66
42. Schneider MR, Sibilia M, Erben RG (2009) The EGFR network
in bone biology and pathology. Trends Endocrinol Metab
20(10):517–524
43. Tamama K, Kawasaki H, Wells A (2010) Epidermal growth
factor (EGF) treatment on multipotential stromal cells (MSCs).
Possible enhancement of therapeutic potential of MSC. J Biomed
Biotechnol 2010:795385
44. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand
is a cytokine that regulates osteoclast differentiation and activa-
tion. Cell 93(2):165–176
Clin Exp Metastasis (2011) 28:649–659 659
123